arzoxifene + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis
Conditions
Osteoporosis
Trial Timeline
Dec 1, 2008 → Oct 1, 2009
NCT ID
NCT00767299About arzoxifene + Placebo
arzoxifene + Placebo is a phase 2 stage product being developed by Eli Lilly for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00767299. Target conditions include Osteoporosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00767299 | Phase 2 | Completed |
| NCT00088010 | Phase 3 | Completed |
| NCT00085956 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoporosis